Middle East and Africa Pen Needles Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Pen Needles Market Size

• The Middle East and Africa  Pen Needles market size was valued at USD 93 million in 2024 and is expected to reach USD 156 million by 2032, at a CAGR of 6.3% during the forecast period
• This growth is driven by the increasing prevalence of diabetes, advancements in pen needle technology, and expanding access to modern healthcare technologies in Gulf and African countries.

Pen Needles Market Analysis

• Pen needles are essential components for delivering injectable medications, particularly insulin, in a convenient and minimally invasive manner. The Middle East and Africa n market is experiencing significant growth due to rising diabetes incidence, technological advancements in needle design, and increased patient awareness.
• The demand for pen needles is significantly driven by the growing diabetic population, favorable reimbursement policies, and the convenience offered by pen devices over traditional syringes.
• Saudi Arabia is expected to dominate the Middle East and Africa Pen Needles market due to its developed hospital infrastructure, high prevalence of diabetes, and active imports of advanced diabetic care products.
• South Africa is projected to register the highest CAGR in the region, driven by public diabetes awareness campaigns, improvements in insurance access, and retail pharmacy expansion in urban centers.
• Standard Pen Needles segment is expected to hold the largest share of 58.5%, due to their widespread use, cost-effectiveness, and compatibility with a variety of pen devices.

Report Scope and Pen Needles Market Segmentation

Pen Needles Market Trends

“Adoption of Safety Pen Needles and Technological Advancements”

• The market is witnessing a shift towards safety pen needles that reduce the risk of needlestick injuries and promote user safety. Manufacturers are focusing on ergonomics and material innovations to make injections less painful and more reliable for chronic conditions such as diabetes.
  • For instance, Terumo Corporation introduced a safety pen needle that automatically retracts post-injection, reducing the chances of accidental pricks. Simultaneously, BD and Novo Nordisk have invested in ultra-thin gauge technologies, with BD’s 2025 launch of its 4mm ultra-fine needle gaining traction among insulin-dependent patients for its improved comfort.

Pen Needles Market Dynamics

“Rising Prevalence of Diabetes and Preference for Self-Administration”

• The growing burden of diabetes across Middle East and Africa is driving the adoption of convenient insulin delivery options, particularly pen devices. Patients increasingly prefer pen needles over conventional syringes due to their simplicity, portability, and reduced injection pain, which enhances treatment compliance and outcomes.

• For instance, the International Diabetes Federation (IDF) estimated over 24 million diabetes cases in the Middle East and Africa region in 2021. Local health ministries in countries such as Saudi Arabia and South Africa have launched awareness campaigns promoting insulin pen usage, increasing demand for pen needles in primary care and retail settings.

Opportunity

“Growth of Online Pharmacies and E-commerce Platforms”

• The rise of digital health platforms and e-commerce infrastructure is enhancing access to pen needles, particularly among tech-savvy and rural populations. Online availability supports flexible purchasing models, including subscriptions and bulk ordering, which cater to the needs of chronic disease patients.

• For instance, in 2025, Embecta partnered with regional e-commerce platforms to enable direct-to-patient distribution in UAE and South Africa. This model significantly improved patient access in remote areas, reducing the reliance on hospital-based supplies.

Restraint/Challenge

“High Cost of Advanced Pen Needles”

• While advanced safety features such as retraction mechanisms and single-use locks improve user safety, they also increase production costs. This cost is often passed on to the consumer, making such products less affordable for the uninsured or underinsured population.

  • For instance, a 2024 survey by the South African Diabetes Association revealed that 32% of insulin-dependent patients reported difficulty affording premium pen needles. The lack of uniform reimbursement policies across Middle East and African countries continues to hinder uptake of advanced safety models.

Pen Needles Market Scope

The market is segmented on the basis of product type, needle length, therapy, mode of purchase, end user, and distribution channel.

In 2025, the Standard Pen Needles segment is projected to dominate the market with the largest share in product type segment

In 2025, the Standard Pen Needles segment is expected to hold the largest share of 60.5%, due to their cost-effectiveness, availability in bulk packaging, and wide distribution via hospitals and pharmacies. The affordability factor is critical for public sector adoption in several African countries.

The Insulin Therapy segment is expected to account for the largest share during the forecast period in therapy segment

In 2025, the Insulin Therapy segment is anticipated to capture a 70.2% share, supported by the growing number of insulin-dependent diabetic patients and government procurement of insulin delivery devices across GCC and North African nations.

“Saudi Arabia Holds the Largest Share in the Pen Needles Market”

• Saudi Arabia is expected to lead the Middle East and Africa Pen Needles market due to its high diabetes burden, investments in specialty care, and strong procurement channels for imported devices.
• The country's collaboration with international diabetes organizations and nationwide screening programs also enhance access and awareness.

“South Africa is Projected to Register the Highest CAGR in the Pen Needles Market”

• South Africa is expected to see the highest growth rate due to the rise in type 2 diabetes, retail pharmacy networks in metros, and digital health engagement for chronic disease management.
• Partnerships with NGOs and community clinics in rural areas further support market growth.Pen Needles Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa  presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• BD (Becton, Dickinson and Company) (U.S.)
• Novo Nordisk (Denmark)
• Ypsomed AG (Switzerland)
• Sanofi (France)
• Terumo Corporation (Japan)
• Owen Mumford Ltd. (U.K.)
• Embecta Corp. (U.S.)
• Allison Medical, Inc. (U.S.)
• UltiMed, Inc. (U.S.)
• Arkray USA, Inc. (U.S.)

Latest Developments in Middle East and Africa  Pen Needles Market

• In January 2025, BD partnered with a major distributor in Saudi Arabia to launch its safety pen needles in government hospitals.
• In February 2025, Novo Nordisk supported diabetes camps in the UAE, distributing pen needle kits to over 5,000 patients.
• In March 2025, Ypsomed expanded its retail presence in South Africa with a new low-cost pen needle line available in major urban pharmacy chains. 
• In April 2025, Terumo Corporation collaborated with Egyptian hospitals to pilot a safe-disposal pen needle system.

SKU-46164